Fever-Tree, the world's leading supplier of premium carbonated mixers, announces that on 12 February 2019, Domenico De Lorenzo, Non-Executive Director of the Company, purchased, in aggregate, 3,500 ordinary shares in the Company at a volume weighted average price of 2,734 pence per ordinary share.
For further information:
Fevertree Drinks plc
Tim Warrillow, Co-founder and CEO
Andy Branchflower, Finance Director
Oliver Winters, Communications & IR Director
+44 (0)20 7349 4922
Numis Securities - Nominated Adviser and Joint Broker
Fever-Tree is the world's leading supplier of premium carbonated mixers for alcoholic spirits by retail sales value, with distribution to over 70 countries worldwide. Based in the UK, the brand was launched in 2005 to provide high quality mixers which could cater to the growing demand for premium spirits, in particular gin, but also increasingly for vodka, rum and whisky. The Company now sells a range of carbonated mixers to hotels, restaurants, bars and cafes ("On Trade") as well as selected retail outlets ("Off Trade").
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the Market Abuse Regulations
Details of the person discharging managerial responsibilities/person closely associated
Domenico De Lorenzo
Reason for the notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Fevertree Drinks plc
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Fever-Tree Drinks Ordinary 0.25p Shares
Nature of the transaction
Acquisition of FQVTF equity via OTC
Price(s) and volume(s)
Date of the transaction
Place of the transaction
London Stock Exchange
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...